FAST NEWS: Everest Medicines loss widens on drug commercialization
The Latest: Everest Medicines Ltd. (1952.HK) announced Tuesday its revenue for the first half of this year surged about 33 times to 302 million yuan ($42.3 million), while its net loss jumped 49%…
FAST NEWS: Everest Medicines gets new drug license from Kezar Life
The latest: Everest Medicines Ltd. (1952.HK) announced Thursday that it has received an exclusive license from Kezar Life Sciences (KZR.US) to develop, manufacture and commercialize Zetomipzomib, a treatment for autoimmune diseases,…
FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
RELATED ARTICLES
-
Everest reaches new heights on growing drug sales
1952.HK -
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
With no cure in sight, drugs firm LianBio begins exit strategy
LIAN.US
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
